McNeil Manufacturing Distress to Drag Into 2013, Constrain 2012 Sales: J&J

April 18, 2012
Efforts to alleviate manufacturing distress at three McNeil Consumer Healthcare plants will take longer and cost more than expected, forcing the Johnson & Johnson (J&J) subsidiary to trickle out OTC drug products through 2013 and its parent company to sweat over sales in 2012, J&J says. Output from McNeil’s consent-decree constrained Fort Washington, Pa., Lancaster, Pa., and Las Piedras, Puerto Rico, plants has been impacted by oversight processes, Louise Mehrota, J&J vice president of investor relations, said Tuesday during the company’s first-quarter earnings call.
Drug Industry Daily